<< Go Back

Metadata

Name
Very Severe Malaria Treated by Intravenous Artesunate
Repository
ClinicalTrials.gov
Identifier
clinicaltrials:NCT04516317
Description
In endemic areas, Plasmodium falciparum malaria exacts a huge public health toll, causing
close to half a million deaths each year. In non-endemic industrialized areas, imported
malaria may develop. In France, around 5000 imported cases occured annually, including 10-15%
of severe malaria.

The criteria for defining severe malaria in endemic areas are established by the World Health
Organization (WHO), and have been adjusted for severe imported malaria. In France, in order
to optimize management, severe imported malaria is separated into two groups: very severe
malaria (VSM) and less severe malaria (LSM). Briefly VSM included coma and/or shock and/or
respiratory failure and/or acidosis and/or hyperlactatemia and/or death during
hospitalization.

In France, severe imported malaria is treated with intravenous artesunate. Little is known
about the management of imported VSM in the ICU with intravenous artesunate.

In a French national multicentric retrospective frame, the main objective of the present
study is to describe in detail: epidemiology, management, outcome and prognostic of very
severe imported malaria treated with intravenous artesunate during the period 2011-2019. The
second objective is to retrospectively compare two groups : VSM treated with intravenous
artesunate in the ICU during 2011-2019 versus VSM treated with intravenous quinine in the ICU
during 2000-2010.
Data or Study Types
clinical trial
Keywords
Severe Malaria, Artesunate, Quinine, Critical Care
Source Organization
Unknown
Access Conditions
available
Year
2020
Access Hyperlink
https://clinicaltrials.gov/ct2/show/NCT04516317

Distributions